Condition
Pancreas Ductal Adenocarcinoma
Total Trials
4
Recruiting
0
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04662879Not ApplicableActive Not Recruiting
Early Detection Initiative for Pancreatic Cancer
NCT02723331Phase 2Completed
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
NCT06980792Completed
Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases
NCT04793932Phase 3Active Not RecruitingPrimary
Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)
Showing all 4 trials